Relationship between acetylcholinesterase inhibition and the development of a myopathy.
D000818:Animals; D002800:Cholinesterase Inhibitors; D008297:Male; D009132:Muscles / Q000187:drug effects / Q000201:enzymology; D009135:Muscular Diseases / Q000139:chemically induced* / Q000201:enzymology; D009388:Neostigmine / Q000494:pharmacology; D009469:Neuromuscular Junction / Q000187:drug effects / Q000201:enzymology; D010261:Paraoxon / Q000494:pharmacology*; D010830:Physostigmine / Q000494:pharmacology; D011220:Pralidoxime Compounds / Q000494:pharmacology; D051381:Rats
D002800:Cholinesterase Inhibitors; D011220:Pralidoxime Compounds; D009388:Neostigmine; D010830:Physostigmine; D010261:Paraoxon